Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Controlled Generation of T cells from Embryonic and Induced Pluripotent Stem cells for Human Immunodeficiency Virus (HIV) Transplantation Therapy

FY 2009-10

Summary
Embryonic stem cells (ESCs) and more recently, induced pluripotent stem cells (iPSCs) derived from mature cells hold great potential for future cell-based therapies due to their ability to differentiate (develop) into all cell types, including blood cells. Blood cells are the principal target and major reservoir of many infectious diseases, including HIV. HIV propagates by debilitating the immune system; specifically T cells that mediate resistance to opportunistic infections. As a potential cell-based therapy for HIV, ESCs have been shown to differentiate into T cells when grown on OP9 mouse bone marrow cell lines transduced to express Delta-like ligand 1 protein (OP9-DL1) (Schmitt et al. Nat. Immunol. 2004). However, the long differentiation time, animal serum protein contaminants and low T cell yield prevent the cells from being used in human trials. We hypothesize that differentiation of T cells from stem cells can be accelerated by deriving iPSCs from mature T cell subsets (or T-iPSCs) as they may retain epigenetic memory of the cell type from which they were derived. Therefore, a cost-effective T cell assay will be developed by differentiating ESCs and patient-derived iPSCs in serum-free media with immobilized DL1 protein presented on polystyrene microbeads. We will also investigate the kinetics of T cell differentiation from T-iPSCs derived from mature and immature T cells, respectively and determine whether the former differentiate at a faster rate than the latter. Lastly, we will derive T-iPSCs from HIV-resistant donor blood samples with rare CCR5 mutant receptors these may be a novel and scalable source of HIV-resistant T cells. Thus, by developing an efficient T cell differentiation technique and combining it with iPSC technology, we will develop a novel T cell vaccine to suppress HIV infectivity and long-term progression to AIDS.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
197225
Name
Shukla Shreya
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Controlled Generation of T cells from Embryonic and Induced Pluripotent Stem cells for Human Immunodeficiency Virus (HIV) Transplantation Therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Blood Development; Cellular Transplantation; Embryonic Stem Cells; Hematopoietic Colony-Forming Cell (Cfc) Assay; Hiv; Immune Response; Induced Pluripotent Stem Cells; Ligand Immobilization; Serum Free Differentiation; T Cell
Abstract
Embryonic stem cells (ESCs) and more recently, induced pluripotent stem cells (iPSCs) derived from mature cells hold great potential for future cell-based therapies due to their ability to differentiate (develop) into all cell types, including blood cells. Blood cells are the principal target and major reservoir of many infectious diseases, including HIV. HIV propagates by debilitating the immune system; specifically T cells that mediate resistance to opportunistic infections. As a potential cell-based therapy for HIV, ESCs have been shown to differentiate into T cells when grown on OP9 mouse bone marrow cell lines transduced to express Delta-like ligand 1 protein (OP9-DL1) (Schmitt et al. Nat. Immunol. 2004). However, the long differentiation time, animal serum protein contaminants and low T cell yield prevent the cells from being used in human trials. We hypothesize that differentiation of T cells from stem cells can be accelerated by deriving iPSCs from mature T cell subsets (or T-iPSCs) as they may retain epigenetic memory of the cell type from which they were derived. Therefore, a cost-effective T cell assay will be developed by differentiating ESCs and patient-derived iPSCs in serum-free media with immobilized DL1 protein presented on polystyrene microbeads. We will also investigate the kinetics of T cell differentiation from T-iPSCs derived from mature and immature T cells, respectively and determine whether the former differentiate at a faster rate than the latter. Lastly, we will derive T-iPSCs from HIV-resistant donor blood samples with rare CCR5 mutant receptors these may be a novel and scalable source of HIV-resistant T cells. Thus, by developing an efficient T cell differentiation technique and combining it with iPSC technology, we will develop a novel T cell vaccine to suppress HIV infectivity and long-term progression to AIDS.
Competitiondate
200911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Shukla, Shreya
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
University of Toronto - $150,000 Grant (2009-10) | Canada Spends